Get the Stockscreener App
38.47
3.20%
-1.27
Moonlake Immunotherapeutics stock is traded at $38.47, with a volume of 273.56K.
It is down -3.20% in the last 24 hours and up +6.92% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$39.74
Open:
$39.74
24h Volume:
273.56K
Relative Volume:
0.66
Market Cap:
$2.69B
Revenue:
-
Net Income/Loss:
$-80.77M
P/E Ratio:
-30.29
EPS:
-1.27
Net Cash Flow:
$-80.80M
1W Performance:
-9.10%
1M Performance:
+6.92%
6M Performance:
-25.70%
1Y Performance:
-8.34%
1-Day Range:
$38.07
$40.75
1-Week Range:
$36.75
$42.62
52-Week Range:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
38.47 | 2.69B | 0 | -80.77M | -80.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Hot Picks in biotechnology - BNN Bloomberg
In the Green: MoonLake Immunotherapeutics (MLTX) Closes at 37.60, Up/Down -4.24 from Previous Day - DWinneX
MoonLake Immunotherapeutics’ SWOT analysis: biopharma stock faces challenges and opportunities - Investing.com
Mariner LLC Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
The biggest biotech funding rounds in April 2025 - Labiotech.eu
MoonLake Immunotherapeutics’ (MLTX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
(MLTX) Investment Analysis - news.stocktradersdaily.com
MoonLake Immunotherapeutics: Promising Clinical Updates and Market Potential Support Buy Rating - TipRanks
RBC Capital Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake Immunotherapeutics (MLTX) receives an Outperform rating from RBC Capital Mkts - knoxdaily.com
MoonLake Immunotherapeutics Shares Surge Ahead of Key Event - TipRanks
MoonLake Immunotherapeutics price target raised to $85 from $81 at BTIG - TipRanks
MoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy Rating - TipRanks
BTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock News - GuruFocus
MoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy Rating - TipRanks
MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating - TipRanks
Ratio Analysis: Unpacking MoonLake Immunotherapeutics (MLTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
MoonLake Immunotherapeutics Hosts Capital Markets Day - TipRanks
Geode Capital Management LLC Purchases 540 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
LPL Financial LLC Buys 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - American Banking and Market News
LPL Financial LLC Purchases 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - GlobeNewswire
Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of “Buy” from Brokerages - Defense World
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
(MLTX) On The My Stocks Page - news.stocktradersdaily.com
Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire Inc.
Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire
How nanobodies will revolutionize immunotherapyBeyond Biotech - Beyond Biotech - the podcast from Labiotech
We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st
Oversold Conditions For MoonLake Immunotherapeutics (MLTX) - Nasdaq
4,500 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by KLP Kapitalforvaltning AS - Defense World
Sei Investments Co. Acquires 1,202 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 1-Year Low – Here’s What Happened - Defense World
MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics’ $500 Million Debt Financing with Hercules Capital - Global Legal Chronicle
MoonLake Immunotherapeutics Term Loan Facility - Leerink Partners
Cantor Fitzgerald maintains Overweight on Moonlake stock - Investing.com Australia
MoonLake secures up to $500 million financing; research update - The Pharma Letter
Cantor Fitzgerald maintains Overweight on Moonlake stock By Investing.com - Investing.com Canada
MoonLake secures $500m for lead drug, plus other financings - Pharmaphorum
Switzerland: MoonLake secures up to US$500m in non-dilutive financing - Investors in Healthcare
MoonLake in US$500m debt deal with Hercules Capital - European Biotechnology Magazine
MoonLake secures up to $500M in financing from Hercules Capital - MSN
MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund - Endpoints News
MoonLake Obtains $500 Million Facility From Hercules Capital - MarketScreener
MoonLake secures hefty financing package to fuel sonelokimab's path to market - FirstWord
MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing - TipRanks
MoonLake Immunotherapeutics Secures $500M Financing for Growth - TipRanks
Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates - MarketScreener
MoonLake Secures up to $500 Million in Non-Dilutive - GlobeNewswire
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):